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This editorial refers to ‘Calmodulin mutations and life-
threatening cardiac arrhythmias: insights from the
International Calmodulinopathy Registry’†, by L. Crotti
et al., on page 2964.
Calmodulin is the primary sensor of intracellular calcium concen-
tration shifts. On binding calcium, calmodulin undergoes large con-
formational changes, allowing rapid transmission of signals to >_300
target proteins. Calmodulin integrity is so crucial that the human
genome contains three independent calmodulin-encoding genes
(CALM1–CALM3), all functional and encoding the same protein, which
further is 100% conserved across vertebrates.1
Given this level of conservation, calmodulin mutations were long
thought to be incompatible with life. It therefore came as a big sur-
prise when a missense mutation was identified in a genetic linkage
study of a large Swedish family with catecholaminergic polymorphic
ventricular tachycardia (CPVT).2 All affected family members carried
a p.Asn54Ile substitution in CALM1 (Take home figure A). The mutated
residue is in the calmodulin N-terminal domain but induces only
minimal changes in calcium binding.3
In the following year, three more CALM missense mutations were
identified among four unrelated infants with long QT syndrome
(LQTS) and recurrent cardiac arrest.4 These de novo missense muta-
tions in either CALM1 or CALM2 expanded the phenotypic spectrum
to include a mechanistically entirely different disease. More reports
followed, with novel missense mutations also identified in CALM3,
and including patients with a diagnosis of idiopathic ventricular
fibrillation (IVF).5,6 It thus became clear that calmodulin mutations
underlie a complex phenotypic spectrum, today known as
calmodulinopathies.7
In this issue of the European Heart Journal, Crotti et al. describe the
International Calmodulinopathy Register (ICalmR), a large collabora-
tive effort to systematically register individuals carrying pathogenic
calmodulin mutations.8 Of 74 included subjects carrying a pathogenic
missense variant in calmodulin, 58 were ascertained from collaborat-
ing centres and 16 from published literature. For the ascertained
cases, the authors used a registry-specific case report file and meticu-
lously recorded the clinical picture, genetic variant, and treatment re-
sponse. This effort has more than doubled the number of known
carriers and brought the count of distinct pathogenic amino acid
changes to 28. The predominant phenotype is LQTS (49%), followed
by CPVT (28%). Other phenotypes include overlapping features of
LQTS/CPVT, IVF, sudden unexplained death (SUD), and neurological
impairments. Most pathogenic mutations are de novo, in line with the
severe phenotypes, with median onset ages as low as 1.5 years for
LQTS and 6 years for CPVT.
With access to this impressive collection of mutation carriers, the
CALM genes are now irrevocably established as major genes for car-
diac arrhythmias. Their missense mutations can cause LQTS, CPVT,
overlapping features of the two, and IVF (Take home figure A). With
the continued collection of detailed clinical information, the ICalmR
will become invaluable for variant interpretation of new CALM muta-
tions associated with cardiac arrhythmia.
Interpretation of missense mutations in asymptomatic individuals
is less clear. Ascertainment of primarily symptomatic and familial
cases is expected to create an upwards bias in estimated penetrance
of identified disease-causing mutations.9 Capturing the full unbiased
phenotypic spectrum and associated penetrance of CALM mutations
will therefore require sequencing of large population-based cohorts.
Of interest, six carriers had neurological impairments unrelated to
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Take home figure Position and main mechanism of arrhythmogenic calmodulin mutations. (A) Upper: three-dimensional structure of calmodu-
lin in calcium-bound form with mutated residues shown in stick representation (PDB-ID: 1CLL). Lower: individual founder mutations shown on the
protein encoded from the representative CALM gene. SUD, sudden unexpected death. (B) Schematic illustration of a cardiomyocyte and the main
molecular mechanism for LQTS, CPVT, and mixed phenotypes, indicating main targets (RyR2 in green, CaV1.2 in blue) and correlation with impact
on calmodulin C-terminal domain calcium affinity loss. Yellow spheres, calcium ions; CaM, calmodulin.
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cardiac arrest, suggesting that some calmodulinopathies may involve
the brain.
Impaired regulation of calcium entry into the cytosol has been sug-
gested to explain how calmodulin mutations can lead to both CPVT
and LQTS (reviewed in Jensen et al.10). For early-onset severe LQTS,
aberrant calcium influx through compromised voltage-gated L-type
calcium channels (CaV1.2) leads to increased action potential
duration. CPVT, in contrast, arise from aberrant regulation of the
intracellular sarcoplasmic reticulum calcium release channel, RyR2.
For both targets, calmodulin inhibits calcium flux in a calcium-
dependent manner, providing a negative feedback loop for appropri-
ate regulation of magnitude and duration of calcium transients.
The question remains of how a mutation in only one of six alleles
encoding identical calmodulin proteins dominantly leads to fatal car-
diac arrhythmias. One possible explanation comes from the ability of
calmodulin to pre-associate with both CaV1.2 and RyR2 at resting
calcium concentrations. Calmodulin mutations that do not interfere
with calmodulin–target binding at low calcium concentrations
can compete with normal calmodulin for binding and impair channel
response to increased calcium concentrations. This results in loss
of negative feedback and excessive calcium release. It is likely because
of these features, shared between CaV1.2 and RyR2 calcium channels,
that one of six alleles can exert a strong dominant negative effect.
Moreover, the mutations may differ in how they affect target binding
affinity, setting the stage for a complex genotype–phenotype
correlation.
Despite this complexity, the emerging picture is an association
between clinical presentation and a mutation’s effect on the calcium
binding affinity of the calmodulin C-terminal domain. According to a
number of reports,10,11 the reduction in calcium affinity correlates
with loss of calcium-dependent inactivation of CaV1.2. The effect on
RyR2 is more complicated and not directly related to calcium affinity.
Thus, in simplified terms, if a mutation has low impact on calcium
binding, CaV1.2 dysregulation and LQTS may be avoided. However,
this will probably unmask CPVT features from aberrant RyR2 regula-
tion (Take home figure B). Mutations among LQTS patients in ICalmR
indeed cluster in C-terminal domain residues directly involved in cal-
cium binding. In contrast, mutations in patients with CPVT occur in
both N- and C-terminal domain residues that do not bind calcium
(Take home figure B). However, neither calcium nor target binding im-
pact of the mutation can fully explain the phenotypic outcome. At
least 10 patients in ICalmR carry the p.Asn98Ser mutation, which
induces a moderate 4-fold reduction in C-terminal domain calcium
affinity. Yet this group represents the entire phenotypic spectrum,
including LQTS, CPVT, IVF, and overlapping features of LQTS/CPVT
(Take home figure A), so environmental factors or modifier genes
must also have an influence.
Curiously, the first missense mutation identified in calmodulin
(p.Asn54Ile), in the large Swedish family with CPVT, had an al-
most undetectable impact on calcium binding.3 It is now clear that
this feature is exactly why the mutation could segregate across
four generations. Related individuals carrying the same inherited
variant are now part of ICalmR, offering a chance to identify po-
tential modifier genes.
Importantly, ICalmR underscores that current treatments for
calmodulinopathies are inadequate. Possibly because of calmodulin’s
role as a calcium signalling hub for a number of important cardiac tar-
gets,12 the full mutation impact is complex and more difficult to treat
than with ‘classical’ arrhythmia genes. A potentially promising option
is a CRISPR- (clustered regularly interspaced short palindromic
repeats) based strategy to remove the mutated allele, as shown for a
severe LQTS CALM2 mutation (p.Asp130Gly).13
Overall, the establishment of ICalmR offers an unprecedented
overview of the remarkable spectrum of phenotypes associated with
calmodulin mutations. It also highlights the serious inadequacies of
current treatments and the need for new approaches. We undoubt-
edly are only at the beginning of unravelling calmodulinopathy preva-
lence and mechanisms.
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